J+D delivers impactful forecasting training at EphMRA 2016 Conference

J+D delivers impactful forecasting training at EphMRA Flagship 2016 Conference

In a dynamic showcase of expertise and collaboration, J+D was honoured to contribute to the esteemed EphMRA’s Flagship Annual Conference in Frankfurt. As a prominent figure in the field of Forecasting, David James, our CEO, brought his insights to the forefront, emphasizing the pivotal role of effective forecasting in the pharmaceutical industry. The conference was a testament to our commitment to advancing industry knowledge.

Teaming up with Andrew Ward, Head of Implementation at J+D, a comprehensive training course was delivered that expertly bridged theory and practice. The audience comprised a diverse mix of senior clients and agencies, all eager to refine their forecasting acumen.

The training session was well received, equipping participants with a clear grasp of various forecasting approaches. We delved deep into optimizing the utilization of market research within forecasts and pinpointed opportunities for refining forecast assumptions.

Attendees unanimously commended the session’s informative content, with special acclaim for the engaging Q&A and interactive exercises that provided hands-on perspectives. The workshop fostered vibrant discussions, debates, and practical application of the principles shared. As one attendee aptly put it, the session was hailed as a “great session enjoyed by everyone.”

J+D Forecasting has a history of delivering impactful training, whether at platforms like EphMRA, EyeforPharma, or tailor-made workshops for individual client companies. Our expertise spans a spectrum of functions and roles, including HQ, Local Affiliates, Business Intelligence, and Brand Teams.

If you would like further information about our approach to forecasting and/or market research, or are interested in a bespoke training session for you and your colleagues, please don’t hesitate to get in touch by clicking here

more insights

Our Pharmaceutical Forecasting Predictions for 2024

As the pharmaceutical industry contends with growing financial pressures, we examine its strategic outlook for 2024. How does the sector intend to align with projected commercial objectives while continuing to meet patient needs and what are the implications for forecasting teams?

Read more >